Key Highlights

Risk & Performance

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Phase 2

3(60.0%)

Phase 1

2(40.0%)

5Total

Phase 2(3)

Phase 1(2)

Loading network data...

Showing 5 of 5 trials

Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke

Role: collaborator

Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome

Role: collaborator

Umbilical Cord Blood Cell (MC001) Transplant Into Injured Spinal Cord Followed by the Locomotor Training

Role: collaborator

Human Umbilical Cord Blood Infusion in Patients with Cerebral Palsy

Role: lead

Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS)

Role: collaborator

All 5 trials loaded